CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
+$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$7.06M |
| 3 |
NVIDIA
NVDA
|
+$6.46M |
| 4 |
Microsoft
MSFT
|
+$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
+$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
+$5.72M |
| 2 |
GSK
GSK
|
+$5.14M |
| 3 |
Pinduoduo
PDD
|
+$3.46M |
| 4 |
Procter & Gamble
PG
|
+$2.91M |
| 5 |
Synopsys
SNPS
|
+$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
ImmunityBio
IBRX
$2.28B
| $378K | 0.04% |
147,754
+13,788
| +10% | +$35.3K |
|
277
CDW
CDW
$22B
| $377K | 0.04% |
2,169
+475
| +28% | +$82.7K |
|
278
MannKind Corp
MNKD
$1.71B
| $376K | 0.04% |
58,475
+5,585
| +11% | +$35.9K |
|
279
Neumora Therapeutics
NMRA
$269M
| $363K | 0.03% |
+34,257
| New | +$363K |
|
280
Indivior
INDV
$3.09B
| $359K | 0.03% |
+28,906
| New | +$359K |
|
281
Dynavax Technologies
DVAX
$1.14B
| $356K | 0.03% |
27,873
+2,669
| +11% | +$34.1K |
|
282
Fortrea Holdings
FTRE
$937M
| $355K | 0.03% |
19,020
+1,787
| +10% | +$33.3K |
|
283
Arcutis Biotherapeutics
ARQT
$2.08B
| $346K | 0.03% |
24,818
+2,336
| +10% | +$32.5K |
|
284
Structure Therapeutics
GPCR
$1.2B
| $343K | 0.03% |
12,634
+1,174
| +10% | +$31.8K |
|
285
Xencor
XNCR
$600M
| $341K | 0.03% |
14,839
+2,946
| +25% | +$67.7K |
|
286
Zeekr
ZK
$7.34B
| $341K | 0.03% |
+12,000
| New | +$341K |
|
287
Affirm
AFRM
$28B
| $338K | 0.03% |
+5,547
| New | +$338K |
|
288
SPDR S&P 500 ETF Trust
SPY
$663B
| $335K | 0.03% |
570
+350
| +159% | +$205K |
|
289
BioCryst Pharmaceuticals
BCRX
$1.72B
| $330K | 0.03% |
43,920
+4,129
| +10% | +$31.1K |
|
290
10x Genomics
TXG
$1.73B
| $326K | 0.03% |
+22,687
| New | +$326K |
|
291
AutoZone
AZO
$71B
| $320K | 0.03% |
100
-50
| -33% | -$160K |
|
292
Travere Therapeutics
TVTX
$1.89B
| $317K | 0.03% |
18,206
+3,494
| +24% | +$60.9K |
|
|
CNTA
293
Centessa Pharmaceuticals
CNTA
$2.42B
| $317K | 0.03% |
18,909
+5,316
| +39% | +$89K |
|
294
Praxis Precision Medicines
PRAX
$858M
| $304K | 0.03% |
+3,952
| New | +$304K |
|
295
Inspire Medical Systems
INSP
$2.47B
| $292K | 0.03% |
+1,574
| New | +$292K |
|
296
Harmony Gold Mining
HMY
$9.1B
| $291K | 0.03% |
35,400
| – | – |
|
297
Zai Lab
ZLAB
$3.49B
| $290K | 0.03% |
11,061
+1,502
| +16% | +$39.3K |
|
298
Spyre Therapeutics
SYRE
$1B
| $290K | 0.03% |
+12,440
| New | +$290K |
|
299
Ocular Therapeutix
OCUL
$2.21B
| $285K | 0.03% |
33,336
+3,347
| +11% | +$28.6K |
|
300
Nurix Therapeutics
NRIX
$742M
| $283K | 0.03% |
15,020
+2,632
| +21% | +$49.6K |
|